IVC Industries sales jump 16.9% in FY 1996; net income down by half due to merger charges.
This article was originally published in The Tan Sheet
IVC INDUSTRIES SALES JUMP 16.9% TO $104.2 MIL. IN FY 1996 for the 12 months ended July 31. Net income was down by half to $296,000 from $593,000 in the previous 12 months. Net earnings in FY 1996 contain a $3.2 mil. charge to earnings after taxes related to the merger and integration of Hall Labs, the Freehold, N.J.-based vitamins and nutritional supplements manufacturer and marketer noted
You may also be interested in...
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.